Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Sponsor
Janssen Research & Development, LLC
Study ID
NCT05757973
Status
Approved For Marketing

Conditions

  • Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Talquetamab — DRUG
    Talquetamab will be administered subcutaneously.

Study Details

The purpose of this pre-approval access program is to give talquetamab monotherapy (treatment with single drug) to participants with relapsed or refractory multiple myeloma (a type of cancer that begins in plasma cells \[white blood cells that produce antibodies\] which has returned or difficult to treat) who have relapsed on or are refractory to all locally available and clinically appropriate treatment and who are not eligible for a clinical trial.

Key Dates

Status verified
Dec 2025

Related Studies